Betterhumans reports that "a new antibody treatment for Alzheimer's has apparently halted its progression in a small human trial." The trial had only five participants, so we should not draw conclusions from such a small sample. "While cognitive function improved marginally in four patients, their condition didn't worsen, which might have been expected after six months. Visual tasks improved in three of the patients and stayed the same in the other two." This work builds on previous research in mice showing that antibodies can clear the buildup of beta amyloid plaques in the brain. This is a promising step towards a much-needed therapy, but there is a way to go yet.